ARCHIVES

In Brief: NCAB Still Without New Appinees As Carter, Califano Delay Drags On; Keele to U. Kansas

This article is from The Cancer Letter archive.

Vol. 05 No. 03 | January 19, 1979

Download PDF Visit The Full Archive

Related Articles

FDA unlikely to pull Iressa from market. Iressa a case study in how not to develop a drug, ODAC member says.

April 1, 2005

Gene Vector Labs Seek Vector Producers

February 23, 1996

ODAC Says Clear Clinical Benefit Required When Sponsors Claim Progression Delay

July 17, 2009

NCI Cooperative Group, Cancer Center Trials Listed

January 25, 2008

FA Drug Approval on Activity, Rather Than Survival Urged By NCU

January 13, 1989

In Brief: NIH gives Advisors $50 Raise, Effective April 1, No Fooling

March 12, 1999